IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
Life review of elderly depression
Development and application of ATR-FTIR spectroscopy for mixture homogeneity in pharmaceutical application
The Increasing Damage in Tubular Cell of Infant Mice’s Kidneys from Carbofuran Exposure during its Mothers’ Lactation Period
Trend of transsexualism problem and its implications towards muslim community in Malaysia
Development and validation of RP-HPLC method for the estimation of pidotimod in tablet dosage form
Evaluation of neurotoxicity of the ethanolic bark extract of Holarrhena pubescens Wall. ex G.Don in mice
Design, synthesis and evaluation of 2-aminobenzimidazole derivatives: strong candidate for PPAR gamma agonists.
Prediction of Heart Disease Using Feature Selection and Random Forest Ensemble Method
Strategies for Antiviral Drugs from Plants by Targeting the Hemagglutinin, Neuraminidase and other receptors of Influenza A virus
The impact of human resource and quality management in health care: A Review
12345678910...
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Development and Evaluation of Febuxostat Sublingual Tablet Formulation

Author: PRASHANT BHIDE, JUBEKA D’CUNHA, NASHOMA FERNANDES
Abstract: Febuxostat drug is recently developed for treatment of gout and classified under BCS class II. For treatment of gout, per-oral route is preferred route of administration, but first pass effect and poor bioavailability limits its application. To overcome these limitations efforts were made to enhance bioavailability of drug via development of sublingual tablet. The formulation was developed by direct compression method, where superdisintegrants like crospovidone, Kyron T-114®, sodium starch glycolate, croscarmellose sodium, Tulsion 339® and Indion 234® were used to enhance solubility and drug release rate. The tablets were evaluated for hardness, thickness, friability, weight variation, drug content, wetting time, in-vitro disintegration time, water absorption ratio and in-vitro dissolution studies. It was concluded that sublingual tablet containing Kyron T-114® and crospovidone showed the highest release (95.37%) at the end of 8 minutes. The optimized batch was subjected for accelerated stability studies. No change in physicochemical properties as well as in drug content and in-vitro release studies was observed.
Keyword: Febuxostat, gout, sublingual, superdisintegrants, solubility
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free